Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates
MWN-AI** Summary
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company, announced its financial results for the year ending December 31, 2025, alongside significant corporate developments. With a focus on rare neurological disorders, Spruce aims to advance its tralesinidase alfa enzyme replacement therapy (TA-ERT) for treating Sanfilippo Syndrome Type B (MPS IIIB). CEO Javier Szwarcberg highlighted the year as highly productive, emphasizing positive interactions with the FDA about the upcoming Biologics License Application (BLA), now expected in Q4 2026.
To strengthen its commercial capabilities ahead of TA-ERT's potential launch, the company appointed Dale Hooks as Chief Commercial Officer, leveraging his extensive experience in rare disease marketing. Furthermore, Spruce secured up to $50 million in growth capital through Avenue Capital Group, which will support the continued development and prospective commercialization of TA-ERT.
Financially, Spruce reported cash and cash equivalents totaling $48.9 million at the end of 2025, anticipating these funds will sustain operations into early 2027. Research and Development (R&D) expenses significantly decreased to $19.5 million from $46.4 million in 2024, primarily due to the cessation of activities related to tildacerfont. In contrast, general and administrative (G&A) expenses rose to $17.0 million, mainly due to higher professional service fees. The total operating expenses for 2025 stood at $36.5 million, down from $61.1 million the previous year, leading to a net loss of $39.0 million—a notable improvement from $53.0 million in 2024.
Looking ahead, Spruce is preparing for the regulatory submission and potential fast-track approval of TA-ERT, which could offer the first disease-modifying treatment option for MPS IIIB, with further corporate updates to follow as the company progresses. For more detailed information, visit Spruce Biosciences' official website.
MWN-AI** Analysis
Spruce Biosciences, Inc. (Nasdaq: SPRB) recently reported its full-year 2025 financial results, highlighting significant strides in the development of its enzyme replacement therapy, TA-ERT, targeting Sanfilippo Syndrome Type B (MPS IIIB). The positive feedback from the FDA following Type B meetings signals potential pathways for accelerated approval, reinforcing investor confidence in the company’s developmental trajectory.
The appointment of Dale Hooks as Chief Commercial Officer is a strategic move that adds substantial experience in rare disease commercialization. This position will be pivotal as Spruce gears up for the potential launch of TA-ERT, anticipated following the BLA submission scheduled for Q4 2026. Notably, securing up to $50 million in growth capital from Avenue Capital Group enhances liquidity, allowing the company to continue advancing its projects despite previous financial losses.
With a year-end cash reserve of $48.9 million, excluding the newly secured funds, Spruce is positioned to sustain its operational plan into early 2027. This should provide sufficient runway to navigate regulatory discussions and operational demands as it heads toward critical milestones. The decrease in research and development expenses—from $46.4 million in 2024 to $19.5 million in 2025—marks a prudent pivot following the cessation of less promising projects, enabling a reallocation of resources towards TA-ERT.
Given these developments, investors should closely monitor Spruce’s progress in the coming quarters, particularly the outcomes following the FDA's review and the effectiveness demonstrated in clinical studies. If TA-ERT achieves approval, it could redefine treatment for MPS IIIB, unlocking significant market potential. However, given the inherent risks associated with biopharmaceuticals, investors should maintain a balanced perspective, weighing potential rewards against operational uncertainties. Overall, Spruce presents a compelling case for investors interested in the biopharma sector, especially within rare disease therapeutics.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Following Positive Type B Meetings with the FDA, BLA Submission for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) on Track for the Fourth Quarter of 2026
Appoints Dale Hooks as Chief Commercial Officer, Strengthening the Company’s Commercial Capabilities in Preparation for a Potential Launch of TA-ERT
Secured up to $50 Million in Growth Capital from Avenue Capital Group
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2025 and provided corporate updates.
“2025 was a very productive year, and our team continues to execute and drive towards key milestones with our tralesinidase alfa enzyme replacement therapy (TA-ERT) program, especially our planned biologics license application (BLA) submission in the fourth quarter of this year and potential commercial launch in MPS IIIB,” said Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer of Spruce Biosciences. “Our recent productive interactions with the FDA have provided clear next steps that strengthen our conviction in the development of TA-ERT for patients and families living with MPS IIIB, for which currently there are no approved therapies. Our appointment of Dale Hooks as Chief Commercial Officer further reflects our conviction and commitment to building our capabilities and commercial infrastructure, as we position ourselves to capitalize on the next chapter of growth at Spruce.”
Recent Corporate Updates
- Held Positive Type B Meetings with the FDA. In February 2026, the company announced the successful completion of two Type B meetings with the FDA regarding its planned upcoming BLA submission for TA-ERT for the treatment of MPS IIIB. The FDA confirmed that the integrated study data from interventional clinical studies of TA-ERT and the available natural history data could potentially serve as an adequate and well-controlled study for purposes of the FDA’s review of the effects of TA-ERT on cerebral spinal fluid heparan sulfate non-reducing end, which could serve as a reasonably likely surrogate endpoint of clinical benefit supporting an accelerated approval. The BLA submission for TA-ERT is anticipated in the fourth quarter of 2026.
- Appointed Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer. Today, the company announced the appointment of Dale Hooks as Chief Commercial Officer, who brings over three decades of biopharmaceutical marketing and commercialization expertise to drive the potential commercial launch of TA-ERT.
- Secured Up to $50 million in Growth Capital from Avenue Capital. In January 2026, the company entered into a loan facility for up to $50 million in growth capital to support the continued advancement and potential commercial launch of TA-ERT. The loan facility has a 42-month term and includes an initial tranche of $15 million, which was fully funded in January 2026, and three additional tranches totaling up to $35 million, subject to the satisfaction of certain terms and conditions of the loan and security agreement.
- Presented Long-term Data of TA-ERT at the 22 nd Annual WORLDSymposium™. In February 2026, data from two different analyses were presented highlighting TA-ERT as potentially the first disease-modifying treatment option for MPS IIIB. One presentation showed that long-term administration of TA-ERT resulted in rapid and durable reduction of heparan sulfate and preserved cognitive and non-cognitive clinical outcomes in patients with MPS IIIB relative to natural history patients. The second presentation included analyses of two siblings diagnosed with MPS IIIB showing that, in an age-matched comparison, one sibling treated with TA-ERT appeared to display higher cognitive, language, and motor functioning relative to the untreated sibling at a similar age. For more information, the two poster presentations can be found on the Spruce Biosciences website at https://investors.sprucebio.com/news-and-events/presentations .
- Added Regulatory and Clinical Development Expertise to the Executive Leadership Team. In February 2026, the company appointed Daven Mody, Pharm.D., as Senior Vice President, Regulatory and Quality, and Bruno Gagnon, B.Pharm., M.Sc., as Senior Vice President, Clinical Development Operations.
- Reauthorization of the Rare Pediatric Disease Priority Review Voucher (PRV) Program. In February 2026, the PRV program was reauthorized through September 30, 2029. This five-year extension restores a key incentive to develop therapies for rare pediatric diseases, allowing companies to receive a fast-track review voucher for approved drugs. TA-ERT has secured Rare Pediatric Disease Designation and is eligible for a PRV, if approved by the FDA.
- Appointed Keli Walbert, a Proven Pharmaceutical Commercial Leader, to the Board of Directors. In December 2025, the company appointed Keli Walbert to its Board of Directors. Ms. Walbert has decades of commercial leadership experience and a proven track record of successful product launches in rare diseases.
Full Year 2025 Financial Results
- Cash and Cash Equivalents: Cash and cash equivalents as of December 31, 2025 were $48.9 million, which excludes the receipt of $15.0 million in gross proceeds under the loan facility with Avenue Capital. The company expects its cash and cash equivalents to fund its current operating plan into early 2027, beyond the anticipated BLA submission for TA-ERT.
- Research and Development (R&D) Expenses: R&D expenses for the year ended December 31, 2025 were $19.5 million compared to $46.4 million for the same period in 2024. The decrease in R&D expenses was primarily related to the cessation of development activities of tildacerfont for the treatment of congenital adrenal hyperplasia (CAH), offset by development activities related to TA-ERT for the treatment of MPS IIIB and the acquisition of SPR202, an anti-corticotropin releasing hormone monoclonal antibody for the treatment of CAH.
- General and Administrative (G&A) Expenses: G&A expenses for the year ended December 31, 2025 were $17.0 million compared to $14.6 million for the same period in 2024, primarily driven by increased professional service fees, offset by a decrease in stock-based compensation expense.
- Total Operating Expenses: Total operating expenses for the year ended December 31, 2025 were $36.5 million compared to $61.1 million for the same period in 2024. Operating expenses include non-cash stock-based compensation expenses of $2.6 million for the year ended December 31, 2025 compared to $5.3 million for the same period in 2024.
Net Loss: Net loss for the year ended December 31, 2025 was $39.0 million compared to $53.0 million for the same period in 2024.
About Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. To learn more, visit www.sprucebio.com and follow us on X , LinkedIn , Facebook and YouTube .
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the ability to seek accelerated approval of TA-ERT for MPS IIIB based on existing clinical data; the content, timing and likelihood of regulatory filings and approvals for TA-ERT, including advancing this program through a BLA submission and potential FDA approval; the potentially transformative clinical impact for TA-ERT; TA-ERT’s eligibility for a PRV; and TA-ERT’s potential to be the first disease-modifying therapy to treat MPS IIIB. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “anticipate,” “could,” “potential,” “on track,” “expect,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Spruce’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Spruce’s business in general, the impact of geopolitical and macroeconomic events, and the other risks described in Spruce’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date.
SPRUCE BIOSCIENCES, INC. | ||||||||
BALANCE SHEETS | ||||||||
(in thousands, except share and per share amounts) | ||||||||
December 31, | ||||||||
2025 | 2024 | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 48,906 | $ | 38,753 | ||||
Prepaid expenses | 353 | 3,177 | ||||||
Other current assets | 2,853 | 2,276 | ||||||
Total current assets | 52,112 | 44,206 | ||||||
Right-of-use assets | 666 | 934 | ||||||
Other assets | 243 | 69 | ||||||
Total assets | $ | 53,021 | $ | 45,209 | ||||
LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 943 | $ | 1,295 | ||||
Accrued expenses and other current liabilities | 9,143 | 12,329 | ||||||
Term loan, current portion | — | 1,622 | ||||||
Total current liabilities | 10,086 | 15,246 | ||||||
Lease liabilities, net of current portion | 419 | 736 | ||||||
Term loan, net of current portion | — | 124 | ||||||
Other liabilities | — | 282 | ||||||
Total liabilities | 10,505 | 16,388 | ||||||
Commitments and contingencies | ||||||||
Stockholders’ equity: | ||||||||
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of December 31, 2025 and 2024 | — | — | ||||||
Common stock, $0.0001 par value; 200,000,000 shares authorized as of December 31, 2025 and 2024; 1,372,043 and 563,042 shares issued and outstanding as of December 31, 2025 and 2024, respectively | — | — | ||||||
Additional paid-in capital | 331,750 | 279,089 | ||||||
Accumulated deficit | (289,234 | ) | (250,268 | ) | ||||
Total stockholders’ equity | 42,516 | 28,821 | ||||||
Total liabilities and stockholders’ equity | $ | 53,021 | $ | 45,209 | ||||
SPRUCE BIOSCIENCES, INC. | ||||||||
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | ||||||||
(in thousands, except share and per share amounts) | ||||||||
Year Ended December 31, | ||||||||
2025 | 2024 | |||||||
Collaboration revenue | $ | — | $ | 4,911 | ||||
Operating expenses: | ||||||||
Research and development | 19,522 | 46,418 | ||||||
General and administrative | 16,991 | 14,644 | ||||||
Total operating expenses | 36,513 | 61,062 | ||||||
Loss from operations | (36,513 | ) | (56,151 | ) | ||||
Interest expense | (90 | ) | (307 | ) | ||||
Change in fair value of warrant liability | (3,500 | ) | — | |||||
Interest and other income, net | 1,137 | 3,422 | ||||||
Net loss and comprehensive loss | (38,966 | ) | (53,036 | ) | ||||
Net loss per share, basic and diluted | $ | (50.83 | ) | $ | (96.40 | ) | ||
Weighted-average shares of common stock outstanding, basic and diluted | 766,598 | 550,146 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20260309462150/en/
Media
Carolyn Hawley
Inizio Evoke Comms
Carolyn.Hawley@inizioevoke.com
media@sprucebio.com
Investors
Monique Kosse
Gilmartin Group
Monique@GilmartinIR.com
investors@sprucebio.com
FAQ**
How does Spruce Biosciences Inc. (SPRB) plan to utilize the $50 million in growth capital secured from Avenue Capital to advance the TA-ERT program for MPS IIIB in preparation for its expected BLA submission?
With the recent appointment of Dale Hooks as Chief Commercial Officer at Spruce Biosciences Inc. (SPRB), what strategies will be implemented to strengthen commercial capabilities ahead of the potential TA-ERT launch?
Given the positive Type B meetings with the FDA, what are the specific next steps for Spruce Biosciences Inc. (SPRB) regarding the BLA submission for TA-ERT, and how do they intend to meet regulatory expectations?
How does Spruce Biosciences Inc. (SPRB) assess the long-term data presented at the WORLDSymposium™ in February 2026 regarding TA-ERT as a potential first disease-modifying treatment for MPS IIIB, and what implications does it have for future growth?
**MWN-AI FAQ is based on asking OpenAI questions about Spruce Biosciences Inc. (NASDAQ: SPRB).
NASDAQ: SPRB
SPRB Trading
18.55% G/L:
$63.55 Last:
33,526 Volume:
$52.47 Open:
